Outpatient treatment of malaria in recently arrived african migrants

Medical Journal of Australia

Volumn 185, Issue 11-12, 2006, Pages 598-601

  Chih, Desmond T ^a   Heath, Christopher H ^a,b   Murray, Ronan J ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; QUININE SULFATE;

ADOLESCENT; ADULT; ARTICLE; AUSTRALIA; DIZZINESS; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBINOPATHY; HUMAN; IMMIGRANT; MAJOR CLINICAL STUDY; MALARIA; MALE; MEDICAL RECORD REVIEW; NAUSEA; NEGRO; OUTPATIENT CARE; PLASMODIUM FALCIPARUM; PLASMODIUM MALARIAE; PLASMODIUM OVALE; SPLENOMEGALY; THROMBOCYTE COUNT;

EID: 33846079805     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00723.x     Document Type: Article

References (20)

1. Bryan JH, Foley DH, Sutherst RW. Malaria transmission and climate change in Australia. Med J Aust 1996; 164: 345-347.
2. Brown G, Anstey N. Malaria. In: Yung A, Macdonald M, Spelman D, et al, editors. Infectious diseases: a clinical approach. 2nd ed. Melbourne: IP Communications, 2005: 316-329.
3. Australian Government Department of Immigration and Multicultural Affairs. Refugee and humanitarian program. Fact sheet 60. Canberra: The Department, 2006. http://www.immi.gov.au/media/fact-sheets/60refugee.htm (accessed Nov 2006).
4. Australian Government Department of Immigration and Multicultural Affairs. Refugee and humanitarian program. Population flows: immigration aspects 2003-04 edition. Canberra: The Department, 2004: 30-35. http://www.immi.gov.au/media/publications/statistics/popflows2003-4/ ch2_pt4.pdf (accessed Nov 2006).
5. Australian Government Department of Health and Ageing. Communicable Diseases Australia. National notifiable diseases surveillance system. Notifications of all diseases by state & territory and year. Canberra: The Department, 2006. http://www9.health.gov.au/cda/Source/ Rpt_2_sel.cfm (accessed Dec 2005).
6. Toovey S, Jamieson A. Co-artemether has been used in ambulatory treatment of falciparum malaria [letter]. BMJ 2002; 324: 1585.
7. D'Acremont V, Landry P, Darioli R, et al. Treatment of imported malaria in an ambulatory setting: prospective study. BMJ 2002; 324: 875-876.
8. Therapeutic Guidelines Limited. Therapeutic guidelines: antibiotic. 12th ed. Malaria. Melbourne: Therapeutic Guidelines Limited, 2003: 120-125.
9. Chih DT, Murray RJ, Heath CH. Outpatient treatment of falciparum malaria in recently arrived African migrants. Australasian Society for Infectious Diseases, annual scientific meeting; 2005 Apr 8-13; Busselton, WA, Australia. Intern Med J 2005; 35 (Suppl): A79.
10. White NJ. Malaria. In: Cook GC, Zumla A, editors. Manson's tropical diseases. 21st ed. London: WB Saunders, 2003: 1205-1295.
11. Toovey S, Jamieson A. Treatment of uncomplicated falcipanum malaria in non-immune and semi-immune individuals exceeding 65kg body weight. S Afr Med J 2004; 94: 443-444.
12. Depoortere E, Guthmann JF, Presse J, et al. Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Trop Med Int Health 2005; 10: 139-145.
13. Genton B, D'Acremont V. Clinical features of malaria in returning travellers and migrants. In: Schlagenhauf F, editor. Travellers' malaria. London: Decker, 2001: 371-392.
14. Looareesuwan S, Chulay J, Canfield C, et al. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am J Trop Med Hyg 1999; 60: 533-541.
15. Lacy MD, Maguire JD, Barcus MJ, et al. Atovaquone/proguanil therapy for Plasmodium falciparum and Plasmodium vivax malaria in Indonesians who lack clinical immunity. Clin Infect Dis 2002; 35: e92-e95.
16. Farnert A, Linberg J, Gil P, et al. Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ 2003; 326: 628-629.
17. Kuhn S, Gill MJ, Kain KC, et al. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune North American traveller to West Africa. Am J Trop Med Hyg 2005; 72: 407-409.
18. Howden BF, Vaddadi G, Manitta J, Grayson ML. Chronic falciparum malaria causing massive splenomegaly 9 years after leaving an endemic area. Med J Aust 2005; 182: 186-188.
19. Stepniewska K, Taylor WRJ, Mayxay M, et al, In-vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother 2004; 48: 4271-4280.
20. van Vugt M, Leonardi E, Phaipun L, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil. Clin Infect Dis 2002; 35: 1498-1504.